Severe self-injurious behavior associated with treatment-resistant schizophrenia: Treatment with maintenance electroconvulsive therapy

Journal of ECT

Volumn 16, Issue 3, 2000, Pages 302-308

  Dean, Charles E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Maintenance electroconvulsive therapy; Self injurious behavior

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; AUTOMUTILATION; CASE REPORT; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; HUMAN; MALE; PSYCHOLOGY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; HALOPERIDOL; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR;

EID: 0034277538     PISSN: 10950680     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124509-200009000-00014     Document Type: Article

References (30)

1. Abrams R. Electroconvulsive Therapy, 3rd ed. New York: Oxford University Press, 1997.
2. Allen SM, Rice SN. Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient. Prog Neuro-Psychopharmacol Biol Psychiatry 1996;20:793-800.
3. Bhatia SC, Bhatia SK, Gupta S. Concurrent administration of clozapine and ECT: A successful therapeutic strategy for a patient with treatment-resistant schizophrenia. J ECT 1998;14:280-3.
4. Breese GR, Criswell HE, Duncan GE, et al. Dopamine deficiency in self-injurious behavior. Psychopharmacol Bull 1989;25:353-7.
5. 2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neurol Transm 1995;102:35-46.
6. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-99.
7. Coffey CE, ed. The Clinical Science of Electroconvulsive Therapy. Washington DC: American Psychiatric Press, 1993.
8. Coppens H, Sloof C, Paans A, et al. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated bill therapy resistant schizophrenic patients. Biol Psychiatry 1991;29:629-34.
9. Criswell HE, Mueller RA, Breese GR. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behavior. Eur J Pharmacol 1989;159:141-7.
10. Dodwell D, Goldberg D. A study of factors associated with response to electroconvulsive therapy. Br J Psychiatry 1989;154:635-9.
11. Farde L, Nordstrom A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side-effects. Arch Gen Psychiatry 1992;49:538-44.
12. Favazza AR, Rosenthal RJ. Diagnostic issues in self-mutilation. Hosp Community Psychiatry 1993;44:134-40.
13. Hall DJ, O'Brien F, Stark C, et al. Thirteen year follow-up of deliberate self-harm, using linked data. Br J Psychiatry 1998;172:239-42.
14. Hatta Y, Hatta S, Saito T. Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats treated chronically with haloperidol. Psychopharmacology 1993;110:383-89.
15. Hawton K, Arensman E, Townsend E, et al. Deliberate self-harm: systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition. BMJ 1998;317:441-7.
16. Hollander E, Kellman D, DeCaria CM, et al. Serotonergic function in borderline personality disorder. In: New Research Program and Abstracts of the 143rd Annual Meeting of the American Psychiatric Association. May 1990, New York.
17. Kapur S, Mann JJ. Antidepressant action and the neurobiologie effects of ECT human studies. In: Coffey CE, ed. The Clinical Science of Electroconvulsive Therapy. Washington DC: American Psychiatric Press, 1993: 235-50.
18. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997;185:348-9.
19. Knable MB, Hyder TM, Murray AM, et al. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biol Psychiatry 1996;40:1191-9.
20. Mann JJ. Neurobiological correlates of the antidepressant action of electroconvulsive therapy. J ECT 1998;14: 172-80.
21. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152:173-8.
22. Pies RW, Popli AP. Self-injurious behavior: Pathophysiology and implications for treatment. J Clin Psychiatry 1995;56:580-8.
23. Rabheru K, Persad E. A review of continuation and maintenance electroconvulsive therapy. Can J Psychiatry 1997;42:476-84.
24. Sackeim HA, Prudic J, Devanand DP, et al. Effect of stimulus intensity and electrode placement no the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993;328:839-46.
25. Sajatovic M, Meltzer HY. The effect of short-term electroconvulsive treatment plus neuroleptics in treatment-resistant schizophrenia and schizoaffective disorder. Convulsive Ther 1993;9:167-75.
26. Schaffer CB, Carroll J, Abramowitz SI. Self-mutilation in personality disorders. J Nerv Ment Dis 1982;170: 468-73.
27. Shapira B, Lerer B, Kindler S, et al. Enhanced serotonergic responsivity following electroconvulsive therapy in patients with major depression. Br J Psychiatry 1992;160:223-9.
28. Simeon D, Stanley B, Frances A, et al. Self-mutilation in personality disorders: Psychological and biological correlates. Am J Psychiatry 1992;149:221-6.
29. Thuppal M, Fink M. Electroconvulsive therapy and mental retardation. J ECT 1999;15:140-9.
30. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: Evidence for two biological groups in schizophrenia. Am J Psychiatry 1989;146:905-8.